Investigation of the Effect of Fasting Duration and Temporary Withholding of GLP-1 RAs on Retained Gastric Contents in Participants Treated With s.c. Liraglutide, Oral Semaglutide or s.c. Semaglutide
Latest Information Update: 17 Nov 2025
At a glance
- Drugs Liraglutide (Primary) ; Semaglutide (Primary) ; Semaglutide (Primary) ; Semaglutide (Primary) ; Semaglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Novo Nordisk
Most Recent Events
- 13 Nov 2025 The protocol has been amended to change in allocation randomized to non-randomized.
- 13 Nov 2025 New trial record